Thromb Haemost 1994; 72(05): 722-727
DOI: 10.1055/s-0038-1648948
Original Article
Schattauer GmbH Stuttgart

Study of the Interaction of Dextran and Enoxaparin on Haemostasis in Humans

Stefan E Matthiasson
1   The Department of Surgery, Lund University, Malmö General Hospital, Malmö, Sweden
,
Bengt Lindblad
1   The Department of Surgery, Lund University, Malmö General Hospital, Malmö, Sweden
,
Thomas Mätzsch
1   The Department of Surgery, Lund University, Malmö General Hospital, Malmö, Sweden
,
Jarl Molin
2   Rhöne-Poulenc Rorer, Sweden
,
Peter Qvarfordt
3   Department of Surgery, Helsingborg Hospital, Helsingborg, Sweden
,
David Bergqvist
4   Department of Surgery, Uppsala University, University Hospital, Uppsala, Sweden
› Author Affiliations
Further Information

Publication History

Received 03 May 1994

Accepted after revision 26 July 1994

Publication Date:
06 July 2018 (online)

Preview

Summary

The effect on haemostatic variables by dextran 70, enoxaparin and their combinations, given in doses of 500 ml i.v. and 40 mg s.c. respectively, was studied in a randomised cross-over fashion in twelve healthy male volunteers. Antifactor-IIa activity, antifactor-Xa activity, APTT, factor VIII, vWF, bleeding time and blood counts were analysed over a 24-h period. Dextran alone did not affect antifactor-IIa activity and antifactor-Xa activity. No difference in antifactor-IIa and antifactor-Xa activity was found for Amax, tmax, AUC0-8 h and AUC0-24 h in the groups treated with enoxaparin or the combination of enoxaparin and dextran. Only minor changes in APTT were observed without statistical significance between the treatment groups. Factor VIII did not change significantly in the three treatment groups. However, vWF was significantly reduced in the dextran and the dextran/enoxaparin group (p = 0.046 and 0.01 respectively) but no difference was found between the two groups. Bleeding time was not significantly increased four hours after administration of the test substances and no difference was found between the individual treatment groups. Our findings indicate that dextran can be combined with enoxaparin, when used in thromboprophylactic doses, without increased risk for bleeding.